August 1^{st<\/sup>, 2013, Haifa, Israel. Sealantis Ltd., a private start-up,\u00a0from the Technion-Israel Institute of Technology that develops alga-mimetic tissue adhesives, reports that it has received the CE Mark for Seal-VTM<\/sup>, its vascular sealant. Seal-VTM<\/sup> is a protein-free bioresorbable sealant, intended to achieve hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels such as the carotid, femoral, brachial and iliac arteries.<\/p>\n}

Seal-V^{TM<\/sup> commences a new generation in tissue sealing. Being alga-mimetic it has an intrinsic ability to bind strongly to both native blood vessels and synthetic grafts, even in wet and moist conditions. In addition, the protein-free composition relieves Seal-VTM<\/sup> from risks associated with the use of protein-based products. Unlike hemostats, which are designed to cause blood to clot, Seal-VTM<\/sup> is not dependent on the presence of blood in order to be effective, and can be used as a prophylactic sealant.<\/p>\n}

“We are excited to be able to introduce Seal-V^{TM<\/sup> to the European market and to provide surgeons with a new and better option for controlling bleeding from suture-lines.” says Mr. Tomer Fuchs, Sealantis CEO. Mr. Fuchs recently joined Sealantis, after serving over two decades in lead executive positions in global companies including Medtronic Ventor, Anorad and Vishay.<\/p>\n}

“Sealantis has been working closely with surgeons to leverage the extraordinary capabilities of its alga-mimetic technology and design products that will be strongly positioned in the multibillion dollars market of wound closure.” Says Dr. Zeev Gilkis, Sealantis Chairman.<\/p>\n

In addition to Seal-V^{TM<\/sup>, Sealantis has a pipeline of advanced solutions for a variety of clinical needs. Among them is a gastro-intestinal sealant, designed to prevent leakage of intestinal content from anastomoses, a potentially fatal complication of GI surgery; an adhesive for space obliteration in esthetic surgeries, which can significantly reduce the recovery time from face and body lifts and innovative combination devices for site-specific drug delivery.<\/p>\n}

Sealantis is currently working on strategic partnerships towards the coming market launch of Seal-V^{TM<\/sup>.<\/p>\n}

\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026<\/p>\n

About Sealantis Ltd.<\/strong><\/p>\n

Sealantis Ltd. is developing a proprietary platform of alga-mimetic tissue adhesives, for a variety of applications and clinical needs in surgical leakage control, tissue adhesion and drug delivery. The Sealantis adhesives are protein-free, and have an extraordinary ability to adhere strongly to internal tissues even in wet environments. Sealantis was founded in 2007 by Prof. Havazelet Bianco-Peled from the Technion, and is funded by the Alfred Mann Institute at the Technion (AMIT).<\/p>\n","protected":false},"excerpt":{"rendered":"

August 1st, 2013, Haifa, Israel. Sealantis Ltd., a private start-up,\u00a0from the Technion-Israel Institute of Technology that develops alga-mimetic tissue adhesives, reports that it has received the CE Mark for Seal-VTM, its vascular sealant. Seal-VTM is a protein-free bioresorbable sealant, intended to achieve hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large… Continue Reading Sealantis Receives CE Mark for Seal-VTM<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[24],"tags":[],"class_list":["post-83860","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\n